Biologic vs conventional DMARDs may offer cardioprotective benefits among patients with PsA, though an increased risk for infection requires vigilance.

Please provide your email address to receive an email when new articles are posted on . Biologic disease-modifying antirheumatic drugs used to treat juvenile rheumatic diseases are excluded entirely ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with tumor necrosis factor inhibitors experienced a shorter time until cancer progression.

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

ATLANTA - New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, demonstrated that polyarticular juvenile idiopathic arthritis patients were ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

Researchers at University of Texas Release New Data on Rheumatoid Arthritis (Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence ...

Relapse occurred in over half of patients with juvenile idiopathic arthritis (JIA) within a year of stopping biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) treatment after ...

ROME — Daily baricitinib, an oral Janus kinase (JAK)1/2 inhibitor, produces rapid clinical improvement in the signs and symptoms of rheumatoid arthritis in patients with active disease who have failed ...

Biologic drugs can be joint savers for rheumatoid arthritis (RA). But even these powerful medications don't always guarantee relief from pain and stiffness. Sometimes the first biologic you try ...

SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today ...